Dean Marc Slagel
Directeur Général chez Esperante BV
Profil
Dean Marc Slagel is currently the Director at Haemostatix Ltd.
and the Managing Director & Director at Altacor Ltd.
He is also the Managing Director at Esperante BV, Esperante Ltd., Esperante AB, and a Non-Executive Director at Oxford Cancer Biomarkers Ltd.
In the past, Mr. Slagel served as the Chief Executive Officer at Esperante Ventures from 2003 to 2007.
He was also the Chairman & Managing Director at Endocells SARL, Director at Pharmaxon SAS, and a Non-Executive Director at Arquer Diagnostics Ltd.
Additionally, he served as an Independent Director at CARA Therapeutics, Inc. from 2005 to 2018.
He was also a Director at Atox Bio Ltd., Theryte Ltd., and Novacta Biosystems Ltd.
Furthermore, he worked as the Director-Global Business Development at Ferring Pharmaceuticals Ltd.
from 1995 to 2004.
He also served as a Director at Canbex Therapeutics Ltd.
and as a Principal at Tillotts Pharma AG.
Mr. Slagel obtained an MBA from Ecole Nationale des Ponts et Chaussées in 2000.
Postes actifs de Dean Marc Slagel
| Sociétés | Poste | Début |
|---|---|---|
Esperante BV
 Esperante BV Investment ManagersFinance Esperante BV (Esperante) is a Dutch based venture capital firm which was founded by Dean Slagel in 2004. Esperante is a seed investor which invests in emerging biotechnology companies engaged in the development of novel therapeutics in areas of major unmet medical need. The firm has a portfolio of investments across France, the UK and the US. The firm provides investee companies with extended management resources, particularly in business development, as a complement to their financial contribution. They also conduct scientific and intellectual property evaluations using confidential life science industry consultants. | Directeur Général | 01/01/2004 |
Altacor Ltd.
 Altacor Ltd. Pharmaceuticals: MajorHealth Technology Altacor Ltd. operates as a specialist ophthalmology company develops and markets a portfolio of products in the fields of dry eye, glaucoma and ocular infection. The company was founded by Francesca Elizabeth Crawford and David Francis Alcraft in 2007 and is headquartered in Theale, the United Kingdom. | Directeur/Membre du Conseil | 03/12/2009 |
| Esperante AB | Directeur Général | - |
Oxford Cancer Biomarkers Ltd.
 Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Directeur/Membre du Conseil | - |
Haemostatix Ltd.
 Haemostatix Ltd. Pharmaceuticals: MajorHealth Technology Haemostatix Ltd. designs and develops solutions for haemostasis and thrombosis. Its products include Rapid and effective haemostatic action which is new class of topical coagulant or haemostat that is applied directly to a wound during surgery to control bleeding, and ready-to-use formulations, blood-free ingredients and a new class with a unique mode of action. The company was founded by Sarah Middleton and Alison Goodall in 2003 and is headquartered in Nottingham, the United Kingdom. | Directeur/Membre du Conseil | - |
Esperante Ltd.
 Esperante Ltd. Investment ManagersFinance Esperante Ltd. operates as a venture investment company controlled by C&P Group Holdings. The company was founded on April 29, 1986 and is headquartered in Maidenhead, the United Kingdom. | Directeur Général | 01/01/2004 |
Anciens postes connus de Dean Marc Slagel
| Sociétés | Poste | Fin |
|---|---|---|
Canbex Therapeutics Ltd.
 Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 25/04/2019 |
| CARA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 07/03/2018 |
Pharmaxon SAS
 Pharmaxon SAS Pharmaceuticals: MajorHealth Technology Despite recent advances in diagnostics, imaging, medical devices and surgical procedures, there has been limited progress in pharmacological treatments for a number of neurological and neuro-oncological pathologies. For pathologies like central and peripheral nervous system injuries, degenerative diseases and tumours of the nervous system, the unmet medical needs are countless and there is growing expectation from the medical community, the patients and their relatives to benefit from clinically proven solutions in the future that will save and/or improve the lives of many. The limited efficacy of approved therapies for some of these pathologies and the orphan nature of others has prompted the urgent need for new researches and therapeutic strategies. At Pharmaxon, as the pioneers of a novel pharmacological approach based on cell mobility modulation, the firm is developing the future 'control keys' for improving the nervous system's endogenous regeneration, modulating neuronal networks plasticity, and inhibiting the processes which underlie tumour cell proliferation and migration. This is obtained by modulating the activity of specific adhesion molecules implicated in cell migration, cell adhesion and cell growth. Based on such a targeted strategy, Pharmaxon is opening up new avenues for the medical management of some serious, poorly-treated, neurology and neuro-oncology pathologies. To date, this has led to three R&D programs which have reached proof-of-principle, confirming the therapeutic potential of this innovative approach, in clinic stage by 2008. | Directeur/Membre du Conseil | 18/12/2012 |
| ░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Dean Marc Slagel
| Ecole Nationale des Ponts et Chaussées | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CARA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 16 |
|---|---|
Tillotts Pharma AG
 Tillotts Pharma AG Pharmaceuticals: MajorHealth Technology Tillotts Pharma AG manufactures pharmaceuticals for treatment of gastrointestinal diseases. The firm specializes in the therapy of the lower gastrointestinal tract. It offers Asacol, Entocort, Colpermin, Tillhepo and VistaPrep. The company was founded in 1986 and is headquartered in Ziefen, Switzerland. | Health Technology |
| Esperante Ventures | Finance |
Novacta Biosystems Ltd.
 Novacta Biosystems Ltd. BiotechnologyHealth Technology Novacta Biosystems Ltd. discovered and developed drugs for treatment of bacterial infections. Its products included lantibiotic/bacteriocin variants, as well as a development candidate for the treatment of C. difficile infection. The company was founded by John Michael Dawson on February 14, 2015 and was headquartered in London, the United Kingdom. | Health Technology |
Haemostatix Ltd.
Haemostatix Ltd. Pharmaceuticals: MajorHealth Technology Haemostatix Ltd. designs and develops solutions for haemostasis and thrombosis. Its products include Rapid and effective haemostatic action which is new class of topical coagulant or haemostat that is applied directly to a wound during surgery to control bleeding, and ready-to-use formulations, blood-free ingredients and a new class with a unique mode of action. The company was founded by Sarah Middleton and Alison Goodall in 2003 and is headquartered in Nottingham, the United Kingdom. | Health Technology |
Esperante Ltd.
Esperante Ltd. Investment ManagersFinance Esperante Ltd. operates as a venture investment company controlled by C&P Group Holdings. The company was founded on April 29, 1986 and is headquartered in Maidenhead, the United Kingdom. | Finance |
Esperante BV
Esperante BV Investment ManagersFinance Esperante BV (Esperante) is a Dutch based venture capital firm which was founded by Dean Slagel in 2004. Esperante is a seed investor which invests in emerging biotechnology companies engaged in the development of novel therapeutics in areas of major unmet medical need. The firm has a portfolio of investments across France, the UK and the US. The firm provides investee companies with extended management resources, particularly in business development, as a complement to their financial contribution. They also conduct scientific and intellectual property evaluations using confidential life science industry consultants. | Finance |
Theryte Ltd.
 Theryte Ltd. Pharmaceuticals: MajorHealth Technology Theryte Ltd. operated as a drug discovery and development company that is committed to bringing new cancer treatments to market. It also operated a virtual model for its discovery and development operations, outsourcing its chemistry, discovery biology and in vivo testing to a number of specialist commercial providers in Europe and North America. The company was founded by Hilmar Meek Warenius, Guenter Herbert Schmidt, Robert John Bishop and Robert Alexander Walker Johnstone on November 20, 1997 and headquartered in Keynsham, the United Kingdom. | Health Technology |
Canbex Therapeutics Ltd.
Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom. | Health Technology |
Endocells SARL
 Endocells SARL BiotechnologyHealth Technology Endocells SARL develops a technology platform for the generation and development of human endocrine cell lines. The firm also engages in cell engineering. The company was founded by Raphaël Scharfmann, Paul Czernichowon and Philippe Ravassard on August 30, 2004 and is headquartered in Paris, France. | Health Technology |
Pharmaxon SAS
Pharmaxon SAS Pharmaceuticals: MajorHealth Technology Despite recent advances in diagnostics, imaging, medical devices and surgical procedures, there has been limited progress in pharmacological treatments for a number of neurological and neuro-oncological pathologies. For pathologies like central and peripheral nervous system injuries, degenerative diseases and tumours of the nervous system, the unmet medical needs are countless and there is growing expectation from the medical community, the patients and their relatives to benefit from clinically proven solutions in the future that will save and/or improve the lives of many. The limited efficacy of approved therapies for some of these pathologies and the orphan nature of others has prompted the urgent need for new researches and therapeutic strategies. At Pharmaxon, as the pioneers of a novel pharmacological approach based on cell mobility modulation, the firm is developing the future 'control keys' for improving the nervous system's endogenous regeneration, modulating neuronal networks plasticity, and inhibiting the processes which underlie tumour cell proliferation and migration. This is obtained by modulating the activity of specific adhesion molecules implicated in cell migration, cell adhesion and cell growth. Based on such a targeted strategy, Pharmaxon is opening up new avenues for the medical management of some serious, poorly-treated, neurology and neuro-oncology pathologies. To date, this has led to three R&D programs which have reached proof-of-principle, confirming the therapeutic potential of this innovative approach, in clinic stage by 2008. | Health Technology |
Arquer Diagnostics Ltd.
 Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom. | Health Services |
Atox Bio Ltd.
 Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Health Technology |
| Esperante AB | |
Ferring Pharmaceuticals Ltd.
 Ferring Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals Ltd. manufactures and produces pharmaceutical products. It offers Zomacton (somatropin) for that treatment of growth failure in children and for girl’s diagnosed with Turners syndrome; GONAPEPTYL (triptorelin), a GnRH agonist that is used for the treatment of children with central precocious puberty; Testim (testosterone gel), a hydroalcoholic topical gel; and PENTASA (mesalazine), which is used for the treatment of inflammatory bowel diseases. The company was founded in 1975 and is headquartered in Middlesex, the United Kingdom. | Health Technology |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Health Services |
Altacor Ltd.
Altacor Ltd. Pharmaceuticals: MajorHealth Technology Altacor Ltd. operates as a specialist ophthalmology company develops and markets a portfolio of products in the fields of dry eye, glaucoma and ocular infection. The company was founded by Francesca Elizabeth Crawford and David Francis Alcraft in 2007 and is headquartered in Theale, the United Kingdom. | Health Technology |
